Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Problem
Ayala Pharmaceuticals was a clinical-stage biopharmaceutical company that aimed to develop small molecule therapeutics for treating specific diseases. The company focused on advancing targeted therapies to address unmet medical needs.
Solution
Ayala Pharmaceuticals sought to create and advance targeted therapies in oncology and other therapeutic areas. Their approach involved the development of small molecule therapeutics designed to treat specific diseases. However, in Q1 2024, Ayala Pharmaceuticals' assets, AL102 and AL101, were acquired by Immunome, Inc.
Target Audience
The target audience included patients with specific diseases and unmet medical needs in oncology and other therapeutic areas.
Features
- Development of small molecule therapeutics
- Focus on targeted therapies
- Research in oncology and other therapeutic areas